NADPH oxidase 1 mediates α-synucleinopathy in Parkinson's disease. - Wikidata - awgldk - TriplyDB

NADPH oxidase 1 mediates α-synucleinopathy in Parkinson's disease.

NADPH oxidase 1 mediates α-synucleinopathy in Parkinson's disease.

http://www.wikidata.org/entity/Q36408665

about

Transcriptional mutagenesis by 8-oxodG in α-synuclein aggregation and the pathogenesis of Parkinson's disease Oxidative stress and Parkinson's disease Seizure activity results in calcium- and mitochondria-independent ROS production via NADPH and xanthine oxidase activation Traumatic brain injury and NADPH oxidase: a deep relationship New insights on NOX enzymes in the central nervous system.One single method to produce native and Tat-fused recombinant human α-synuclein in Escherichia coli.Matrix metalloproteinase-3 causes dopaminergic neuronal death through Nox1-regenerated oxidative stress NOX2 As a Target for Drug Development: Indications, Possible Complications, and Progress.Formation and Implications of Alpha-Synuclein Radical in Maneb- and Paraquat-Induced Models of Parkinson's Disease.PKCδ mediates paraquat-induced Nox1 expression in dopaminergic neurons.Rodent models of Parkinson's disease: beyond the motor symptomatology NADPH oxidase in brain injury and neurodegenerative disorders Antioxidant gene therapy against neuronal cell death.The role of β-adrenergic blockers in Parkinson's disease: possible genetic and cell-signaling mechanisms.β-Ecdysterone Protects SH-SY5Y Cells Against 6-Hydroxydopamine-Induced Apoptosis via Mitochondria-Dependent Mechanism: Involvement of p38(MAPK)-p53 Signaling Pathway.Mito-Apocynin Prevents Mitochondrial Dysfunction, Microglial Activation, Oxidative Damage, and Progressive Neurodegeneration in MitoPark Transgenic Mice.Therapeutic potential of NADPH oxidase 1/4 inhibitors.Systemic QSAR and phenotypic virtual screening: chasing butterflies in drug discovery.Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease ω-3 fatty acid eicosapentaenoic acid attenuates MPP+-induced neurodegeneration in fully differentiated human SH-SY5Y and primary mesencephalic cells.Deregulation of α-synuclein in Parkinson's disease: Insight from epigenetic structure and transcriptional regulation of SNCA.Mitoapocynin Treatment Protects Against Neuroinflammation and Dopaminergic Neurodegeneration in a Preclinical Animal Model of Parkinson's Disease.α-Mangostin Inhibits α-Synuclein-Induced Microglial Neuroinflammation and Neurotoxicity.NADPH oxidases in Parkinson's disease: a systematic review.CCL11 enhances excitotoxic neuronal death by producing reactive oxygen species in microglia.Therapeutic effects of fucoidan in 6-hydroxydopamine-lesioned rat model of Parkinson's disease: Role of NADPH oxidase-1.Curcumin affords neuroprotection and inhibits α-synuclein aggregation in lipopolysaccharide-induced Parkinson's disease model.Implantation of Neural Probes in the Brain Elicits Oxidative Stress.

P2860

Q26796502-9C61718D-3004-4E5E-9644-D0314B0F6C80 Q26798897-D0C22FAD-6ED0-42CE-829A-50ACFB77DF4F Q27331435-2E786F54-0BA2-438F-B065-E60EDA1505FF Q28080903-B6879DD0-2B5C-4B3A-8F03-17DF7A69D3A3 Q33632673-3E0A9267-1C28-4610-95AA-DA4BA9B94B83 Q34655246-60149834-8732-46A4-8549-D8E71D32D899 Q34764783-864EC295-0E62-489E-9F5A-CF548E982ACA Q35985407-55346793-97BA-432D-920F-F7806E7764A4 Q36260495-D3FA83C9-3E5A-459F-8590-3EA314966679 Q37138890-3104FF70-B0F5-4DFD-AEAE-4C6A3A65A601 Q37343565-F710B43E-6944-4AB0-8DA0-017EC174DBA9 Q37589114-91E007BF-844B-46AD-BFFA-D812B792C76C Q37647941-073407E3-4927-475D-A97B-4127809179A0 Q38108496-56E69B45-195E-47E5-AE1D-09E9E2896EAD Q38768249-C2024AA4-7BBF-450E-8A40-4CE88E340C21 Q38855994-666CED14-E0C2-4106-92B8-E14C49F5DCB4 Q38858553-C42AC76B-C123-4C0C-B992-62668C2F88DE Q39169235-E7CC0B52-0FB5-462A-A8CA-26E51968469A Q39205712-994BC7D6-29BD-48A7-A3DE-9D580DACEBC7 Q39252312-B5050760-E5E9-4C3D-A564-21103DF5EF78 Q39264615-59FD7D90-F026-42CB-8269-9EAF623491D3 Q41349377-9D0C8E1C-D504-4757-8BEC-1AA83DCA6796 Q42739828-DA8C3FAA-6CDA-43C6-87AF-3B9C18AE8CBB Q46262582-7F677E8F-834E-4DD2-BE41-5D8B3AB75A61 Q46699381-A6EFA3A3-372F-42A3-BA2B-567467388244 Q46814011-E0481A7C-2897-4842-982F-641541B95ACA Q47659411-5BECF5F8-3574-45A2-AC6A-165BF7495E30 Q50328717-D4D6214F-B71D-4636-AE59-D376EC0873FB

P2860

NADPH oxidase 1 mediates α-synucleinopathy in Parkinson's disease.

http://www.wikidata.org/entity/Q36408665

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

NADPH oxidase 1 mediates α-synucleinopathy in Parkinson's disease.

@ast

NADPH oxidase 1 mediates α-synucleinopathy in Parkinson's disease.

@en

type

label

NADPH oxidase 1 mediates α-synucleinopathy in Parkinson's disease.

@ast

NADPH oxidase 1 mediates α-synucleinopathy in Parkinson's disease.

@en

prefLabel

NADPH oxidase 1 mediates α-synucleinopathy in Parkinson's disease.

@ast

NADPH oxidase 1 mediates α-synucleinopathy in Parkinson's disease.

@en

P1433

Q36408665-E49FD20B-C63E-4A50-AD11-BEC7B2CB1512

P1476

Q36408665-0F8864CE-6ED9-4C1A-93C1-84209DC0291B

P2093

Q36408665-0A772169-8772-477E-BF2C-8AA0853B2FC5

Q36408665-2B71B5EC-E276-4320-B2A6-BCEEAC3D88F0

Q36408665-34215BBD-0055-4705-A548-859FF62EC7F5

Q36408665-908E99B6-7167-405A-BE5E-AB2FDE27741B

Q36408665-C080D0A7-0E60-4A97-8A97-07D54A48E474

Q36408665-E45883A3-5B22-4F83-A5E2-E0A5C6E618F1

Q36408665-E78D146C-3D14-4492-9C28-E224232B3AE7

P2860

Q36408665-04982BC0-E061-4C5B-B044-0B4305AE6DD1

Q36408665-0B504D19-CEE4-427D-A0BB-E1E7C4BA55CF

Q36408665-1014E5A4-F6FB-49A6-A580-8BC839394623

Q36408665-1DA08036-0629-4B51-82E1-3F4E5EA2533C

Q36408665-2529388C-9EAE-4446-8CC4-E45A8538E2AE

Q36408665-329A0113-26D4-4439-8BE6-B3CA9DFCFC43

Q36408665-3605481D-7048-48FE-95EC-6BBA38581907

Q36408665-40D89649-28E1-48E9-B781-0A4CA50A56E9

Q36408665-4539ACA6-489F-4128-99DE-46FEC5A1CB92

Q36408665-478E5065-3626-4629-94C1-AC5E84AC20B4

P304

Q36408665-C1C30B46-DE8B-4B25-A79F-59FDC98590E9

P31

Q36408665-EF9A4034-E49D-4150-A56C-DC7E8A05C30E

P356

Q36408665-73E80E00-9441-465C-83CD-DBA99A83CFB7

P407

Q36408665-7716EFB8-CA7C-454F-889C-955C2966B611

P433

Q36408665-819F585F-5B50-41E2-9A35-63C9F89B00F4

P478

Q36408665-42B21468-25B4-4320-BF97-98BA88044334

P577

Q36408665-37A35809-31AD-4971-8790-37FCB2819B16

P5875

Q36408665-F7544718-35AD-464E-A36A-DCD91121C84C

P698

Q36408665-FA634F47-9886-45B0-B929-EC2D2FCA2242

P921

Q36408665-AE77F2F4-B4CB-4391-88D8-808AE0EA11AC

P932

Q36408665-C69656CB-F08D-4A0B-AFBA-9AFC935972F0

P356

JNEUROSCI.2246-12.2012

P1433

Journal of Neuroscience

P1476

NADPH oxidase 1 mediates α-synucleinopathy in Parkinson's disease.

@en

P2093

Ana Clara Cristóvão

http://www.w3.org/2001/XMLSchema#string

Dong-Hee Choi

http://www.w3.org/2001/XMLSchema#string

Eugene Bok

http://www.w3.org/2001/XMLSchema#string

Goun Je

http://www.w3.org/2001/XMLSchema#string

Seung Don Yoo

http://www.w3.org/2001/XMLSchema#string

Subhrangshu Guhathakurta

http://www.w3.org/2001/XMLSchema#string

Yoon-Seong Kim

http://www.w3.org/2001/XMLSchema#string

P2860

alpha-Synuclein and neuronal cell death

SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model

PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons

Functional dissection of the alpha-synuclein promoter: transcriptional regulation by ZSCAN21 and ZNF219

Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies

Pesticides and Parkinson's disease--is there a link?

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

alpha-Synuclein locus triplication causes Parkinson's disease

Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease

The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia

P304

14465-14477

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1523/JNEUROSCI.2246-12.2012

http://www.w3.org/2001/XMLSchema#string

P407

P433

42

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232281293

http://www.w3.org/2001/XMLSchema#string

P698

23077033

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3501265

http://www.w3.org/2001/XMLSchema#string